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Abstract
Background: Matched sequencing of both tumor and normal tissue is routinely used to classify variants of
uncertain significance (VUS) into somatic vs. germline. However, assays used in molecular diagnostics focus on
known somatic alterations in cancer genes and often only sequence tumors. Therefore, an algorithm that reliably
classifies variants would be helpful for retrospective exploratory analyses. Contamination of tumor samples with
normal cells results in differences in expected allelic fractions of germline and somatic variants, which can be
exploited to accurately infer genotypes after adjusting for local copy number. However, existing algorithms for
determining tumor purity, ploidy and copy number are not designed for unmatched short read sequencing data.
Results: We describe a methodology and corresponding open source software for estimating tumor purity, copy
number, loss of heterozygosity (LOH), and contamination, and for classification of single nucleotide variants (SNVs) by
somatic status and clonality. This R package, PureCN, is optimized for targeted short read sequencing data, integrates
well with standard somatic variant detection pipelines, and has support for matched and unmatched tumor samples.
Accuracy is demonstrated on simulated data and on real whole exome sequencing data.
Conclusions: Our algorithm provides accurate estimates of tumor purity and ploidy, even if matched normal samples
are not available. This in turn allows accurate classification of SNVs. The software is provided as open source (Artistic
License 2.0) R/Bioconductor package PureCN (http://bioconductor.org/packages/PureCN/).
Keywords: Purity, Ploidy, Heterogeneity, Whole exome sequencing, Hybrid capture, Copy number, Loss of heterozygosity,
Cell lines
Background
Accurate knowledge of tumor purity and copy number
is required to understand allelic fractions (the ratios of
non-reference to total sequencing reads) of genomic
alterations, in particular for determining the clonality
of alterations, for somatic vs. germline labelling in the
absence of matched normal samples, and for identifying
regions of loss of heterozygosity (LOH). Furthermore,
especially in datasets with high variance in tumor purity
across samples, adjustment of purity is necessary for
accurate calling of copy number alterations.
Existing algorithms are not designed for hybrid capture
sequencing data [1–5], do not support samples without
matched normal samples [6–11], and/or do not auto-
matically and accurately adjust for tumor purity and
ploidy (e.g. [12–15]). Most existing algorithms use copy
number data for purity and ploidy estimation and then
utilize germline allelic fractions only for the ranking of in-
ferred purity/ploidy solutions, instead of using copy num-
ber and allelic fractions of germline and somatic mutations
jointly or inference of these values. There is also an unmet
demand for methods distinguishing private germline from
somatic mutations, and for doing so, algorithms need very
accurate estimates of purity and local copy number to
achieve acceptable accuracy [16]. Furthermore, for SNV
classification, not only total copy number is needed, but
also the maternal and paternal copy numbers are important
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provide allele-specific copy numbers (e.g. [3, 8]). A reliable
algorithm for classifying private variants would make
sequencing of matched normal samples less important,
especially in settings such as diagnostics where variants
of uncertain significance (VUS) are typically ignored, but
where secondary, exploratory analyses are common.
We present a flexible Bioconductor/R package that inte-
grates with (but does not require) standard GATK-based
[17] pipelines, utilizes standard Bioconductor infrastructure
[18–21] for data import and export, supports both matched
and unmatched samples, and was tested on targeted panels.
PureCN provides well-tested copy number normalization
and segmentation functionality, but can be easily integrated
with existing copy number pipelines. While the algorithm
builds on existing ideas developed for genome-wide array
data, its novel likelihood model was designed and optimized
for short read sequencing data with or without matched
normal samples. In contrast to existing solutions, this likeli-
hood model identifies artifacts caused by incorrect read
alignment or contamination of DNA from other individuals,
incorporates the important information provided by
somatic point mutations, can use copy number and
SNV information jointly, and supports uneven tiling of
targets across the genome. PureCN further supports copy
number and LOH calling in 100% pure and unmatched
samples such as cell lines. Our software is thus widely
applicable, both in diagnostic and research settings.
Implementation
Data pre-processing
By default, we start with coverage data calculated from
BAM files by either the PureCN calculateBam
CoverageByInterval function or by the GATK
DepthOfCoverage tool. Both calculate total and aver-
age coverages of all targeted genomic regions (Fig. 1a).
While it is possible to extract coverage data from
germline and somatic single nucleotide variant (SNV)
data directly, calculation of coverage across the complete
targeted genome utilizes all on-target data and makes the
correction of assay-specific capture biases straightforward
by utilizing a pool of normal samples. Other biases, most
importantly GC bias, are library-specific and should be cor-
rected separately. We thus first GC normalize the coverage
data using standard methods [10, 12]. Additionally, SNV
data in VCF format are obtained separately using standard
third-party tools such as MuTect [22]. All BAM files, from
Fig. 1 Flowchart of the PureCN data pre-processing pipeline and algorithm. a PureCN usually starts from BAM files and calculates average
and total coverages for all targeted genomic regions. Coverage data are then corrected for GC-bias. Concurrently, SNVs are called using third-party tools such
as MuTect [22]. b The main algorithm takes the generated data from tumor as input. If multiple process-matched normal samples are available, the algorithm
can optionally use this pool of normal samples to (i) adjust SNV allelic fractions for non-reference mapping bias and (ii) select a best process-matched normal
to obtain a clean copy number profile. A pool of normal samples is recommended when matched normal samples are not available. After copy-number
normalization and segmentation, local optima for tumor purity and ploidy are obtained via 2D grid search. Integer copy numbers are then assigned to all
segments for all local optima via Simulated Annealing. Final likelihood scores are obtained by fitting SNVs to all local optima. If necessary, samples are flagged
for manual curation. Steps in bold font indicate alternative start points, allowing incorporation of PureCN into third-party copy number pipelines
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tumor and normal samples, are processed with this pipeline
depicted in Fig. 1a. If the tumor and normal samples
are matched, then the SNV caller can be run in
matched mode to obtain somatic status of variants.
Copy number normalization and segmentation
Next, for calculating target-level copy number log-ratios,
a suitable normal sample is ideally selected from a pool
of high quality process-matched normals via principal
component analysis (PCA) of GC-normalized coverage
data (Fig. 1b). By default, the normal sample with minimum
Euclidean distance to the tumor on the first 3 principal
components is used for normalization. This procedure
selects a normal sample with sufficient coverage and similar
library-specific coverage biases compared to the tumor
sample. Since coverage is the major source of variance,
we scale the coverage for this step to a maximum (defaults
to 100×) for samples exceeding this maximum. It is also
possible to use the n best normals and then provide the
normalization function an (weighted) averaged coverage,
which is useful when the normal samples are sequenced to
significantly lower target coverage than the tumor samples.
Our implementation is modular and allows the incorp-
oration of existing segmentation algorithms. In the default
setting, log-ratios of coverage between the tumor sample
and PCA-matched normal sample are smoothed and
segmented using a weighted version of the circular binary
segmentation algorithm implemented in the DNAcopy R
package (CBS) (Venkatraman and Olshen, 2007). We set
target weights proportional to the inverse of the coverage
ratio standard deviations in the pool of normals using the
function createTargetWeights. Thus, targets with
highly variable coverage in normals, either due to tech-
nical artifacts (e.g. mappability issues) or common germ-
line variants, are down-weighted in the segmentation. If
no pool of normals is available, the standard, unweighted
CBS is used. If a pool of normal samples is available, we
further exclude target intervals with low median coverage
(by default lower than 20% of the chromosome median).
While heterozygous germline SNPs are sparse, they do
provide valuable information for improving segmentations
obtained by coverage data only. The number of targets with
heterozygous SNPs usually varies between 5 and 15%,
depending whether SNPs in flanking regions of targets
are included or removed. We find that including SNPs
in 50 bp flanking regions add a significant number of
high coverage SNPs and we therefore use 50 bp as default,
but optimal parameters depend on coverage and assay and
should be tuned. Breakpoints of borderline significance
(P > 0.001) are removed in our default segmentation
when mirrored allelic fractions (1- allelic fraction if allelic
fraction >0.5) of known heterozygous germline variants
(dbSNP) are not significantly different (P > 0.2, two-sided
t-test) in the corresponding neighboring segments.
Segments are further tested for copy number neutral
LOH. To this end, we recursively identify within all seg-
ments the optimal breakpoints that minimize the standard
deviations of germline allelic fractions; only if the differ-
ence in allelic fraction of the neighboring candidate seg-
ments reaches a given alpha threshold, the breakpoint is
accepted (two-sided t-test). We note that if the assay
includes copy number tiling probes highly enriched in
heterozygous SNPs, an algorithm (e.g. FACETS or PSCBS
[8, 23]) that jointly segments coverage and allelic fractions
can sometimes provide better results and we provide a
convenient wrapper function for using the PSCBS method
over the default. Finally, we use Ward’s hierarchical clus-
tering to find segments with similar copy number log-
ratios and mirrored allelic fractions. These segments are
normalized to have the same mean log-ratios.
Purity and ploidy estimation
We first use a 2D grid search to find tumor purity and
ploidy combinations that fit the log-ratio profile well.
The log-ratios ri in a segment i are assumed to be nor-
mally distributed with standard error σri, the latter we
estimate from the segmentation (i.e., is set to the average
standard deviation of log-ratios in a segment). The log-
ratios are a function of copy number C and purity p:















A difference between our algorithm and most others
designed for whole genome data is that segment likeli-
hoods are essentially weighted by the number of exons
per segment, not by the base pair segment size l. This is
an advantage when targets are not evenly distributed, for
example in smaller gene panels. The segment size is
used for calculating the tumor ploidy in the denominator,
using the tumor copy numbers of all j segments. Equation
(1) assumes that ploidy in normal is 2; PureCN thus de-
tects sex and excludes sex chromosomes for males.
Our algorithm can also take as input already segmented
data and σri, for example when matched SNP6 data is avail-
able. The algorithm will then generate simulated exon-level
data given a specified interval file and will use the same
likelihood model. Typically, multiple purity/ploidy combi-
nations are equally likely, and we will later use a Bayesian
framework to pick the combination that best fits allelic frac-
tions of germline and somatic single nucleotide variants
(SNVs), without necessarily requiring knowledge whether
these variants are indeed germline or somatic. All local op-
tima identified in the grid search are tested via this frame-
work. This grid search is typically performed in less than
2 min on an average workstation and significantly reduces
Riester et al. Source Code for Biology and Medicine  (2016) 11:13 Page 3 of 13
the search space for the more computationally intensive fit-
ting of variant allelic fractions.
In the grid-search, we assume that all ploidy values are
possible, although this is not necessarily true since copy
numbers are not continuous. The assumption allows the
calculation of the likelihood scores in (1) without knowing
the exact integer copy numbers of all segments required in
the denominator. Thus every local optimum is in a second
step optimized by Simulated Annealing, in which integer
copy numbers are assigned to all segments and the purity
estimate is fine-tuned. More precisely, Eq. (1) is used to
calculate integer copy number posterior probabilities for all
segments, P(Ci), and we use a heated Gibbs sampler to
optimize the segment copy numbers until convergence,
which is, in general, achieved after few iterations. Purity is
similarly optimized via heated Gibbs sampling using a speci-
fied grid (default from 0.15 to 0.95 in steps of 0.01). We con-
sider copy numbers from 0 to 7 and include a “sub-clonal”
state based on a univariate distribution, used for all seg-
ments that do not fit integer values and for capturing high-
level amplifications with copy number >7 (Carter, et al., [1]).
Mis-calibrated copy number log-ratios (slightly right or
left-shifted) can cause shifts in maximum likelihood ploidy
estimates when assigning integer copy numbers to seg-
ments. In our optimization, we thus re-calibrate the
log-ratios by Gibbs sampling. By default, log-ratios are
right or left-shifted by at most 0.25 times the mean segment
log-ratio standard deviation. If the optimized ploidy is one
chromosome higher or lower than the ploidy identified the
grid search, additional optimizations are attempted with
this re-calibration range increased to up to 1 times the
log-ratio standard deviation. The purity/ploidy solution
is finally discarded if the optimized ploidy is, after these
extensive re-calibrations, still not similar to the grid search
ploidy. Mis-calibrations happen when major copy number
alterations are not captured and are thus much more fre-
quent in targeted panels without dedicated copy number
tiling probes than in whole exome data.
SNV likelihood model
The next step in our approach is to determine somatic
status of SNVs. We fit the allelic fractions of SNVs, pro-
vided as VCF file for example generated by the MuTect
algorithm [22], to the purity/ploidy combinations of all
local optima. We first specify the necessary prior prob-
abilities for SNVs being somatic (vs. germline), P(g). If a
matched normal is available, we set it to 0.999 for somatic
mutations and 0.0001 for germline variants (note that these
do not need to add up to 1, since these priors are assigned
to different variants). The reason for not setting these priors
to 1 and 0 is to limit the impact of single variants, in
particular avoiding rare artifacts dominating the likelihood
scores. Without matched normals, we rely on the public
databases dbSNP and COSMIC, namely we set the
prior to 0.95 if the variant is found more than 2 times
in COSMIC; to 0.0005 if the variant found in dbSNP;
to 0.01 if found in both COSMIC and dbSNP; and other-
wise to 0.5. Accurate calibration of these priors is challen-
ging, since these correspond to error rates in the public
databases and these errors are sequence specific, for
example errors in COSMIC often cluster in segmental
duplications with low coverage and are thus different
for different assays. All priors used in the PureCN like-
lihood model can be tuned by the user. In practice,
since the vast majority of variants are germline and
present in dbSNP, final results of purity and ploidy are
very robust to the choice of these priors.
The expected allelic fraction f of variant i is a function
of tumor purity p, copy number C, germline status g (1
for germline, 0 for somatic) and multiplicity M, which is
the number of chromosomes harboring the mutation:
E f i½  ¼
pMi þ gi 1 − pð Þ
pCi þ 2 1 − pð Þ ð2Þ
Note that this does not model homozygous germline
variants (g is not allowed to be 2), since these are unin-
formative and are by default removed. Somatic mutations
further by definition always have a multiplicity larger than
0 (1 or larger for mono-clonal mutations). We model the
sampling variance of allelic fractions using a beta distribu-
tion with n being the number of covered reads. The likeli-
hood of observing a particular allelic fraction given these
parameters is defined as in Carter et al. (Carter, et al., [1]):
L f ijp;Ci; gi;Mi; ni
  ¼ Beta E f i½ j nif i þ 1; ni 1−f ið Þ þ 1ð Þ ð3Þ
Note that heterozygous germline SNPs with observed
allelic fraction significantly different from 0.5 [using (3), P <
0.05] in the matched normal or in a sufficient number of
samples in the pool of normals are also removed. These are
often SNPs in segmental duplications or other low-quality
genomic regions. Smaller non-reference biases in regions of
high mappability cause only minor shifts in expected allelic
fractions and are not explicitly modeled, but we provide
functionality to adjust observed allelic fractions, for example
by estimating position-specific scaling factors in a large pool
of normal samples. With increasing coverage, these biases
may lead to very small likelihoods for correct purity and
copy number values if not adjusted correctly, causing a para-
dox where increasing coverage decreases accuracy, and we
therefore define a maximum value for n (defaults to 300×).
Incorporating the uncertainty of copy number calculated
via Eq. (1), (3) becomes:
L f ijp; gi; Mi; n
  ¼X
Ci∈ 0::7f gP Cið ÞL f ijp;Ci; g;Mi; nð Þ ð4Þ
We finally integrate over the uncertainty of germline
status and multiplicity to find for each variant the most
likely state:
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Possible values for M depend on the number of mater-
nal and paternal chromosomes, with K denoting the
smaller one of the two chromosome numbers. We assume
that the multiplicity of germline variants in a segment cor-
respond to the maternal and paternal chromosome num-
bers with probability PK, by default set to 0.999. By not
setting this value to 1, we make the likelihood model more
robust to segmentation errors. For somatic mutations,
we further always allow the mutation of a single
chromosome; this assumes that multiplicities larger
than 1 are the result of copy number alterations, almost
never of independent mutations resulting in identical base
changes. The prior probabilities for M are thus:






if Mi ¼ Ki ∨ Mi ¼ Ci−Ki ∨ Mi≤1 ∧gi ¼ 0
 
0 if K i > ⌊Ci=2⌋




Where ns denotes the number of utilized “allowed”
states covered in the first case of Eq. (6) for a given K
and C combination. This value can range from 1 to 4; in
germline SNPs ns it would be 1 when both maternal and
paternal copy numbers are equal and 2 when these two
numbers differ. Somatic mutations can have two add-
itional states, the mutation of a single chromosome
(when M = 1) and a sub-clonal state (when M < 1). This
sub-clonal state is by default modelled in Eq. (5) by re-
placing the invalid M = 0 and g = 0 state (somatic muta-
tions by definition have M > 0) with M = 1/3 and g = 0.
This M value represents the expected average cellular
fraction of sub-clonal mutations.
We assume flat priors for K, P Kið Þ ¼ 1Ciþ1 , but note
that databases of samples could provide better priors
(see [1] for a related karyotype likelihood model). For
example LOH in the TP53 tumor suppressor is very
common in various cancer types; we would thus find the
corresponding copy number state K = 0 and C = 1 fre-
quently in these cancer types. If low ploidy solutions
can explain the data well, then this prior further results in
favoring low over high ploidy solutions (which is why K is
defined over the complete copy number range). We
however noticed that haploid solutions are often ranked
relatively high in low purity samples, because the
P gi;Mijf i ; ni
  ¼ P Mið ÞP gi
 
















L f ijp;Cij; gij; Mij; ni
  ð5Þ
Fig. 2 Example output of PureCN, applied to whole exome sequencing data of a male breast cancer patient. The first step in PureCN is fitting
exon-level copy-number to all purity and ploidy combinations in a 2D grid search. The colors visualize the copy number fitting log-likelihood
score from low (blue) to high (red). The numbers indicate local optima and their final rank after fitting both copy number and allelic fractions of
germline SNPs and somatic mutations
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lack of one tumor chromosome does not result in
sufficiently unbalanced germline allelic fractions in
those samples. We thus give haploid and diploid so-
lutions the same prior probability when the tumor
purity is below 35%. Regions of LOH are classified
as LOH or not, using the most likely segment state
as determined in Eq. (5); a segment is in LOH if C = 1 or
K = 0.
To model possible contamination from other individuals’
DNA, we optionally include two additional SNV states. The
first models homozygous germline SNPs that were not re-
moved because reference alleles were sequenced from
the contaminated DNA, resulting in allelic fractions
lower than 1 (Eq. 7). The second state (Eq. 8) models
SNPs where the non-reference allele is only present in




Fig. 3 B-allele plot of the male breast cancer metastasis example. In all 3 panels, a dot represents a germline SNP (in single sample mode a predicted
germline SNP). The first panel (a) shows their allelic fractions along the genome. Background colors visualize chromosomes and vertical dotted lines
centromere positions. The bold black lines visualize the expected (not the average) allelic fractions in the segment. These expected values are calculated
using the estimated purity and the total (sum of maternal and paternal copy number) and minor (the minimum of maternal and paternal
copy number) segment copy numbers (Eq. 5). These are visualized in black and grey, respectively, in the (b) and (c). Panel (b) shows the copy
number log-ratios, panel (c) the final, inferred integer copy numbers. SNPs plotted as triangles or crosses were classified as potential homozygous or
contamination, respectively
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now a function of purity, tumor copy number and con-
tamination rate c:
E f i½  ¼
pCi þ 2 1 − p−cð Þ
pCi þ 2 1 − pð Þ ð7Þ
E f i½  ¼
c
pCi þ 2 1 − pð Þ ð8Þ
The prior probabilities for these states are set to a
non-zero value for germline variants (present in dbSNP)
only, because the dimension (i.e. number of possible states)
for novel variants is much higher, thus rarely resulting
in likelihood scores low enough to impact purity/ploidy
selection. We set contamination rate and prior prob-
ability for this state by default to a low 0.01. The main
motivation for this functionality is to provide a bin for
germline variants that do not fit any other state, and
more specialized tools should be used to detect con-
tamination. We note that if matched normal samples
are available, then this step is not crucial, since contam-
ination is identified as non-germline by variant calling
algorithms, whereas without matched normal samples,
the presence of variants in dbSNP results in high germ-
line prior probabilities.
In samples of 100% purity, homozygous SNPs should




Fig. 4 B-allele plot of the male breast cancer primary tumor sample. Panels are as described in Fig. 3, but data is for the matched primary tumor run in
tumor-only mode, without the matching normal sample. The lower purity results in log-ratios and B-allele frequencies closer to 0 and 0.5, respectively
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SNPs in mono-clonal LOH regions. For high purity samples
without matched normal samples, we therefore optionally
provide yet another germline state, the homozygous state.
Any observed reference reads are assumed to be inde-
pendent sequencing errors resulting in identical base
pairs (by default occurring at rate ε = 10−3/3) and the
state likelihoods are then modeled with a binomial
distribution. Flat prior probabilities independent of
ploidy are applied.
Finally, for variants most likely being somatic, we calcu-
late the fraction h of tumor cells harboring the mutation:
h ¼ f
M





The SNV-fit likelihood is the sum of the log-likelihood
scores of the most likely states for all variants. The tumor
purity/ploidy combinations are finally sorted by sum of
the log-likelihood scores of both copy number and SNVs.
Our implementation provides an additional post
optimization, in which purity is optimized using both
copy number and allelic fractions in the SNV fitting
step. This is achieved by adding purity as additional
dimension in the denominator of Eq. 5. In default mode,
this is turned off, i.e., allelic fractions are only used to select
the most likely purity/ploidy combination from the copy
number fitting. The accuracy gain for copy number calling
is typically marginal in high quality samples with sufficient
coverage as used in this benchmarking (data not shown).
For classification of variants by somatic status, we rec-
ommend turning this feature on as small inaccuracies
in purity can decrease the performance significantly since
the distributions of allelic fractions of the different SNV
states often overlap. By default, we use flat priors for tumor
purity, but users can provide priors for all tested purity
values in the grid.
Automated calling
If the algorithm is applied to many samples, it is important
to flag samples that likely need manual curation. We flag
samples of potentially low quality (noisy segmentations,
high AT- or GC-dropout, sample contamination), samples
where the maximum likelihood solution has characteristics
rarely seen in correct solutions (rare ploidy, excessive LOH,
excessive homozygous losses), and samples that are difficult
to call (non-aberrant, poly-genomic). We further provide
functionality for automatically removing very unlikely
optima via a bootstrapping procedure, in which variants
are sampled with replacement and optima are then re-
ranked. Optima which never rank high in any bootstrap
replicate are removed. Bootstrap values may also flag
samples for manual curation when PureCN identified
multiple plausible solutions. Finally, we calculate for each
sample a goodness-of-fit score of the SNV fitting, ranging
from 0 to 100%, where 0% corresponds to the worst pos-
sible fit and 100% to a perfect fit. We defined the worst
possible fit as a fit in which observed allelic fractions differ
on average by 0.2 from their expected values. Both low pur-
ity and high ploidy solutions are biased towards higher
scores; low purity allelic fractions have a low variance in
general and high ploidy solutions are complex and usually
find good fits. Compared to log-likelihood scores, however,
this goodness-of-fit score is intuitive and allows a straight-
forward flagging of very poor fits.
Results
Example
We applied our implementation to whole exome sequen-
cing data from a male breast cancer metastasis sample [24].
Fig. 5 Accuracy of germline vs. somatic variant labeling. This figure displays the allelic fractions of correctly and incorrectly labeled variants for two
samples run in MuTect and PureCN without matched normal sample. The ground truth was obtained by running MuTect with matched normal
sample. The first was a primary tumor sample with purity of 0.5, the second a metastasis sample with purity of 0.7. Due to the lower purity of the
primary tumor sample, the distributions of allelic fraction overlap less, making the prediction easier. The bars for the 4 different categories are stacked
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After segmentation, initial estimates of purity and ploidy
were obtained in a grid search, and allelic fractions of SNVs
were fitted to all local optima. Figure 2a shows a surface
plot, in which likelihood scores were colored from blue
(low) to red (high), with the numbers showing the final
ranks of all tested local optima after fitting both copy num-
ber and allelic fractions. Figure 2b displays a histogram of
tumor vs. normal copy number log-ratios for the maximum
likelihood solution (number 1 in Fig. 2a). The height of a
bar in this plot is proportional to the fraction of the genome
falling into the particular log-ratio copy number range. For
a given purity and ploidy combination, the vertical dot-
ted lines visualize the expected log-ratios for all rele-
vant integer copy numbers; it can be seen that most of
the log-ratios of the maximum likelihood solution align




Fig. 6 Accuracy on simulated data. The two panels (a) and (b) show the high correlation of true and inferred maximum likelihood tumor purity
and ploidy in simulated data. Colors visualize the simulated purity, ranging from 20 to 80%. Excluding the samples with tumor purity of 20%, the
correlations increase to 0.98 for purity and 0.95 for ploidy [(c) and (d)]. Note that for almost all of the samples, the correct solution was considered, but
was not always ranked as maximum likelihood solution. Panel (e) shows for all samples, including the 20% samples, the ploidy correlation of the best
considered solution (minimizing the Euclidean distance in scaled purity and ploidy), for example selected in a hypothetical perfect manual curation
(Pearson 0.98). Panel (f) shows the histogram of ranks of the best solution over all samples
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Germline variant data are informative for calculating
integer copy number, because unbalanced maternal and
paternal chromosome numbers in the tumor portion of
the sample lead to unbalanced germline allelic fractions
(Eq. 2, Fig. 3a). Chromosomes 1p, 12p, 16q, and 16p
show deviations from the expected allelic fraction of 0.5
suggestive of structural variants. Figure 3b shows the
corresponding copy numbers, first as log-ratios and then
as inferred integer copy numbers. Combining these data
with the allelic fraction data (Fig. 3a), we find that the
LOH of chromosome 1p is copy number neutral, 12p
and 16q have LOH due to copy loss and there is a copy
number gain of 16p. For this sample, PureCN returned a
very similar maximum likelihood purity and ploidy estimate
when run with and without the matched normal sample
(0.7 for purity and 2.001 for ploidy). When run without
matched normal sample, we classified 129 private variants
as somatic or germline, and 88.3% were correctly classified.
All misclassified variants had allelic fractions between 0.35
and 0.5, the expected fractions for heterozygous somatic
and germline, respectively. For the same patient, a primary




Fig. 7 Accuracy on simulated ultra-deep sequencing data (400×) from a 560 gene panel. This shows the same plots as in Fig. 6, but forsimulated data from
a targeted panel. Due to the higher sequencing depth, even the low purity samples have in general ploidy estimates close to the true ploidy
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process-matched normal sample resulted in a clean copy
number profile. Some genomic regions display biased allelic
fractions of heterozygous germline SNPs, for example the
largest one on chromosome 3q, which are automatically re-
moved when matched normal samples are available. In
tumor-only mode, these SNPs can be removed by using a
pool of normal samples as described in the Method section.
The lower tumor purity of 0.5 resulted in a larger difference
in expected fractions for somatic and germline variants.
With this spread, the accuracy increased to 97.7% (Fig. 5).
Most of the private variants exclusive to the either primary
tumor or metastatic sample displayed allelic fractions
significantly lower than expected for a heterozygous somatic
variant, indicating sub-clonality and are labelled such
by PureCN [24].
Benchmarking
We first demonstrated the accuracy of our algorithm on
simulated data: artificial whole exome data (100×) and
data from an ultra-deep sequenced (400×) 560-gene
panel, with purity ranging from 20 to 80%, and ploidy
ranging from 1 to 6 (Figs. 6 and 7). Simulated data was
based on whole exome and targeted panel data from
normal samples. In brief, simulated genomes were
first generated by using random segmentations ob-
tained from the TCGA breast cancer study [25] as
template. Assuming copy number of 2 for all targets,
normal coverage was then scaled to simulated copy
number and then scaled to desired target coverage.
Allelic fractions were then sampled using Eq. (3),
with SNPs randomly assigned to either the maternal
or the paternal chromosome. For the whole exome
data, the Pearson correlation of true and inferred
maximum likelihood purity and ploidy was 0.98 and
0.80, respectively. When excluding samples with pur-
ity lower than 35%, the correlations increased to
0.98 for purity and 0.95 for ploidy. For the gene
panel, the correlation of purity and ploidy was 0.96






Fig. 8 Comparison with existing proprietary ABSOLUTE implementation. In panel (a) and (b), our purity and ploidy estimates (y-axis), respectively,
are plotted against the estimates from Foundation Medicine. Triangles indicate solutions flagged by PureCN for manual curation. c Compares
copy number ratios of amplifications and homozygous deletions in 40 different samples. d shows the corresponding absolute copy numbers
adjusted for purity and ploidy. Copy numbers were capped at 7 in both algorithms, the default copy number cutoffs for non-focal amplifications
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We next applied our algorithm to real sequencing data
from 58 cancer samples (Fig. 8), which were obtained from
a commercial vendor using a targeted panel with copy
number tiling probes [26] and internally using whole
exome sequencing on remnant DNA. Libraries were con-
structed with Illumina TruSeq, captured with the Agilent
SureSelect Whole Exome v4 baits, and sequenced on an
Illumina HiSeq2500 as 100 base-pair paired-end reads. No
matched normal data was available. Foundation Medicine
provides purity and ploidy estimates obtained using an
unpublished proprietary algorithm that was systematically
validated using cell line mixture experiments [26]. To our
knowledge, this is the only other algorithm validated for
unmatched targeted sequencing data.
We observed a Pearson correlation of 0.92 when com-
paring our maximum likelihood purity estimate with the
estimate provided from Foundation Medicine. Comparing
estimated ploidy values, we found that 89.7% of samples
showed concordant ploidy estimates (since the vast
majority of samples were diploid, the low Pearson correl-
ation of 0.38 is driven by the 10.3% discordant outliers).
Discordant samples were mainly of low quality (low purity
and one sample with high AT-dropout). Four samples were
flagged for manual curation, including two of the three
samples for which the PureCN maximum likelihood ploidy
estimate was wrong (Fig. 8a and b). These two samples are
shown in Additional file 1. Additionally, since copy number
fitting involves a Simulated Annealing optimization
for assigning integer copy number to segments, we
examined the number of iterations until convergence
(Additional file 2). Convergence was usually achieved
before iteration 20, and we found no correlation of
number of iterations and purity or ploidy.
We compared copy numbers of all amplifications and
homozygous deletions called by Foundation Medicine and
found a good concordance of copy numbers un-adjusted
(Fig. 8c) and adjusted (Fig. 8d) for purity and ploidy. Forty
samples had at least one called amplification or deletion.
The Pearson correlation of un-adjusted copy number ratios
was 0.93 (Fig. 8c). For 85% of the samples, the mean
difference in absolute copy numbers was within ±1
when comparing PureCN with the Foundation Medicine
calls (Fig. 8d).
Limitations
PureCN was designed for high-coverage (>100×) targeted
sequenced data. Quality of results obtained from lower
coverage data depends on tumor purity and evenness of
coverage. Furthermore, due to increasing sampling variance
of allelic fractions, accurate classification of SNVs becomes
challenging with decreasing coverage. The automatic
classification of all SNVs further results in longer runtimes
than other purity/ploidy inference tools (whole-exome
runtime for PureCN 1.6 is about an hour without post-
optimization), currently practically prohibiting the use
of PureCN for whole-genome data. Future versions might
see runtime improvements due to implementations of
heuristics that eliminate unlikely local optima early.
Conclusions
PureCN is a flexible open source R/Bioconductor package
that assists in understanding allelic fractions of SNVs. Since
purity adjusted copy number is important to this end,
PureCN is also a state of the art copy number caller for
hybrid capture sequencing data, supporting tumor sam-
ples with or without matching normal samples.
Additional files
Additional file 1: Whole-exome samples with wrong maximum
likelihood solutions. (DOCX 604 kb)
Additional file 2: Number of Simulated Annealing iterations. (PDF 5 kb)
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